2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5434 Tumor burden-adapted bridging therapy improves CD19 CAR-T outcomes in relapsed or refractory large B-cell lymphoma: A phase II, single-center prospective study

Zi-Xun Yan, Niu Qiao2, Shu-Bei Wang3, Lingshuang Sheng, MD4, Rong Shen, MD5, Ting-Ting Pan6, Qi Song7, Xu-Feng Jiang8, Hong-Mei Yi, MD, PhD9, Wen Wu10, Li Wang11, Shu Cheng, MD12, Peng-Peng Xu13, Wei Li Zhao III, Certified Doctor14
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Department of Radiation Oncology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Department of Critical Care Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Department of Radiology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Department of Nuclear Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Department of Pathology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
13 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background:

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for refractory or relapsed large B-cell lymphoma (R/R LBCL), yet early relapse or inadequate responses remain common. High tumor burden is associated with inferior prognosis by CAR-T infusion but not routinely used to guide bridging strategies.

Methods:

We conducted a prospective, single-arm, open-label phase II study evaluating a tumor burden–adapted bridging approach before CD19 CAR-T infusion, aiming to improve treatment response and outcomes in R/R LBCL patients. Patients were stratified by baseline longest diameter index (LDI, ≤4 cm vs >4 cm), with chemotherapy-based (chemo-based) bridging for higher tumor burden and immunomodulatory therapy-based (IM-based) bridging for lower tumor burden. After lymphodepletion, response-adapted maintenance was administered: complete responders received zanubrutinib for 3 months, whereas partial responders received zanubrutinib plus the PD-1 inhibitor tislelizumab. The primary endpoint was CR rate at 3 months.

Results:

From June 2023 to December 2025, 48 patients were infused (IM-based, n=38; chemo-based, n=10). Baseline characteristics were generally well balanced between groups, except for the CAR-T product. The CR rate at day 28 was 60.4%, which was increased to 77.1% at 3 months, 83.3% at 6 months, and remained as 81.2% at 12 months. With a median follow-up of 26.8 months from leukapheresis, median PFS and OS were not reached in the overall population. Notably, IM-based bridging yielded superior early CR (M3 CR: 81.6% vs. 60.0%) and markedly enhanced in vivo CAR-T expansion, with higher peak CAR-T cell count (p<0.001), AUC0-28d (p=0.001), and expansion rate (p=0.002). Median PFS was not reached in the IM-based group versus 12.0 months in the chemo-based group (HR 1.06, p=0.942); median OS was not reached versus 29.9 months (HR 0.76, p=0.905). Among the 48 patients, grade≥3 AEs were primarily haematological, with neutropenia (75.0%) and thrombocytopenia (50.0%) being most common. Haematological toxicities were comparable between bridging strategy groups. Grade ≥3 CRS was observed in 10.5% of patients in the IM-based group and 0.0% in chemo-based group. Grade ≥3 ICANS occurred in 2.6% and 0.0% of patients in the respective groups.

Conclusions:

Tumor burden–adapted bridging combined with response-adapted immune maintenance was associated with deeper remission and durable disease control after CAR-T therapy in R/R LBCL.

Zi-Xun Yan: No relevant conflicts of interest to declare.